---
schema_version: "secwatch.filing_event.v1"
accession: "0001161697-23-000378"
form_type: "8-K"
ticker: "KRMD"
cik: "0000704440"
company_name: "KORU Medical Systems, Inc."
filed_at: "2023-06-27T23:59:59+00:00"
generated_at: "2026-06-13T16:39:00.687502+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# KORU Medical appoints Andrew LaFrence as CFO, effective July 10, 2023

## Summary
- Andrew LaFrence brings 39 years of finance/accounting experience; previously CFO at Vyant Bio and Surmodics, 26 years at KPMG.
- Base salary of $350k per year; eligible for annual cash bonus up to 50% of base salary.
- Inducement option to purchase 300,000 shares of common stock, vesting 25% annually over 4 years.
- Tom Adams, interim CFO, will continue as VP of Financial Planning and Analysis.
- LaFrence will support the Vision 2026 growth strategy and scaling of the business.

## SEC filing metadata
- accession: 0001161697-23-000378
- form_type: 8-K
- ticker: KRMD
- cik: 0000704440
- company_name: KORU Medical Systems, Inc.
- filed_at: 2023-06-27T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/704440/000116169723000378/0001161697-23-000378-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/704440/000116169723000378/form_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001161697-23-000378
- JSON: https://secwatch.observer/filing/0001161697-23-000378.json
- Plain text: https://secwatch.observer/filing/0001161697-23-000378.txt

## Key facts
- Executive change
  Thomas Adams changed role as Vice President of Financial Planning and Analysis at KORU Medical Systems, Inc..
  - Action: role change
  - Role: Vice President of Financial Planning and Analysis
  source text: Thomas Adams, Interim Chief Financial Officer, will continue as the Company’s Vice President of Financial Planning and Analysis upon the appointment of Mr. LaFrence.
  evidence_url: https://www.sec.gov/Archives/edgar/data/704440/000116169723000378/0001161697-23-000378-index.htm
- Executive change
  Andrew D. C. LaFrence was appointed as Chief Financial Officer at KORU Medical Systems, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Andrew D. C. LaFrence has been employed by KORU Medical Systems, Inc. (the “Company”) to serve as its Chief Financial Officer commencing July 10, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/704440/000116169723000378/0001161697-23-000378-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.